| Literature DB >> 34736363 |
Tao Shaolin1, Feng Yonggeng1, Kang Poming1, Mei Longyong1, Shen Cheng1, Fang Chunshu1, Wu Licheng1, Tan Qunyou1, Deng Bo1.
Abstract
Objective: To evaluate the clinical significance of an optimized approach to improve surgical field visualization and simplify anastomosis techniques using robotic-assisted sleeve lobectomy for lung or bronchial carcinoma. Method: A total of 26 consecutive patients who underwent sleeve lobectomy between January 2017 and April 2020 were enrolled in the study. The cohort included 11 cases of robotic-assisted surgery (RAS group) and 15 cases of mini-thoracotomy (MT group). RAS was performed via an exclusive optimized approach utilizing the "3 to 4-6 to 8/9" four-port technique. Retrieved demographical and clinical data included operation time, anastomosis time, blood loss, chest drainage time and volume, postoperative pain scores, complications, white blood cell (WBC) levels, and duration of hospital stay and follow-up.Entities:
Keywords: RAS-assisted thoracic surgery; mini-thoracotomy surgery; sleeve lobectomy
Mesh:
Year: 2021 PMID: 34736363 PMCID: PMC8573479 DOI: 10.1177/15330338211051547
Source DB: PubMed Journal: Technol Cancer Res Treat ISSN: 1533-0338
Figure 1.Right upper sleeve lobectomy using RAS (surgical processes prior to anastomosis)
Figure 2.Right upper sleeve lobectomy using RAS (anastomosis processes)
Figure 3.Evaluation of postoperative bronchius protrusion via chest CT (three months after RA sleeve lobectomy).
Clinical demographical characteristics of RAS and MT groups
| Data | RAS (n = 11) | Mini-thoracotomy (n = 15) | P-value | |
|---|---|---|---|---|
| Sex | Male | 10 (38.46) | 13 (50) | .619 |
| Female | 1 (3.85) | 2 (7.69) | ||
| Age (years, Mean ± SD) | 54.82 ± 9.21 | 56.53 ± 8.25 | .622 | |
| Smoking status | Yes | 10 (38.46) | 12 (46.15) | .426 |
| No | 1 (3.85) | 3 (11.54) | ||
| Basic diseases | Yes | 7 (53.8) | 6(46.2) | .251 |
| No | 4 (36.4) | 9 (60) | ||
| Tumor location | RUL | 7 (26.92) | 10 (38.46) | .500 |
| LUL | 0 | 2 (7.69) | ||
| LLL | 2 (7.69) | 1 (3.85) | ||
| RSB | 0 | 1 (3.85) | ||
| RMB | 1 (3.85) | 1 (3.85) | ||
| LMB | 1 (3.85) | 0 | ||
| Maximum diameter of tumor (cm, Mean ± SD) | 2.76 ± 1.30 | 3.49 ± 1.69 | .243 | |
| Pathological type | Squamous carcinoma | 8 (30.77) | 10 (38.46) | .741 |
| Others | 3(11.54) | 5 (19.23) | ||
| Postoperative TNM stage | I | 5(21.74) | 6 (26.08) | .982 |
| II | 3 (11.54) | 5 (19.23) | ||
| III | 2 (7.69) | 2 (7.69) |
Note:
i: In RAS group: two diabetes cases; two chronic obstructive pulmonary disease cases; one hyperthyroidism case; one case with history of pulmonary tuberculosis; one arrhythmia case.
ii: In MT group: five hypertension cases and one diabetes case.
iii: RUL: right upper lobe; LUL: left upper lobe; LLL: left lower lobe; RSB: right secondary bronchus; RMB: right main bronchus; LMB: left main bronchus.
iv: Large-cell carcinoma, adenocarcinoma, and epithelial-myoepithelial carcinoma.
v: Small-cell carcinoma, large-cell carcinoma, epithelial-myoepithelial carcinoma, Castleman's disease (mixed type), and hamartoma.
Comparison of clinical outcomes between RAS and MT groups
| Data (Mean ± SD) | RAS group (n = 11) | MT group (n = 15) | P-value | |
|---|---|---|---|---|
| Operation time (min) | 189.73 ± 36.41 | 225.33 ± 38.19 | .025i | |
| Intraoperative blood loss (ml) | 154.55 ± 121.36 | 170 ± 90.24 | .712 | |
| Total number of lymph node removed (n) | 20.60 ± 9.94 | 17.79 ± 7.87 | .447 | |
| Thoracic drainage time (d) | 9.64 ± 4.95 | 9.27 ± 8.01 | .894 | |
| Total thoracic drainage volume (mL) | 2662.27 ± 1291.05 | 1992.67 ± 1226.95 | .191 | |
| Postoperative pain score | 4.23 ± .26 | 4.91 ± .51 | .000ii | |
| Postoperative hospital stay (d) | 12.18 ± 5.25 | 12.53 ± 7.12 | .891 | |
| WBC( × 109/L) | Preoperative | 5.96 ± 1.22 | 6.57 ± 2.17 | .409 |
| Postoperative Day1 | 12.48 ± 3.42 | 15.09 ± 3.34 | .064 | |
| Postoperative Day3 | 7.09 ± 1.41 | 9.58 ± 2.61 | .012iii | |
| Postoperative Day7 | 6.66 ± 1.43 | 9.38 ± 2.27 | .003iv | |
Note: statistical powers: i: .752; ii: .989; iii: 0.842; iv: .936
Figure 4.Kaplan–Meier curve showing that cases in two groups had no significant differences and present satisfactory short-term outcomes.